Celgene Corporation (CELG) Shares Sold by Fiera Capital Corp
Fiera Capital Corp lessened its stake in Celgene Corporation (NASDAQ:CELG) by 13.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,687 shares of the biopharmaceutical company’s stock after selling 5,060 shares during the quarter. Fiera Capital Corp’s holdings in Celgene Corporation were worth $4,115,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in CELG. Thompson Davis & CO. Inc. boosted its holdings in shares of Celgene Corporation by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Celgene Corporation in the 1st quarter valued at $118,000. Motco lifted its holdings in shares of Celgene Corporation by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 159 shares in the last quarter. Penserra Capital Management LLC acquired a new position in shares of Celgene Corporation during the 2nd quarter valued at $129,000. Finally, Acropolis Investment Management LLC acquired a new position in shares of Celgene Corporation during the 2nd quarter valued at $144,000. Institutional investors own 79.16% of the company’s stock.
Celgene Corporation (NASDAQ:CELG) opened at $103.35 on Friday. The firm has a market cap of $78,999.38, a P/E ratio of 15.68, a price-to-earnings-growth ratio of 0.77 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Corporation has a 12 month low of $94.55 and a 12 month high of $147.17.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.58 EPS. equities research analysts expect that Celgene Corporation will post 6.67 earnings per share for the current year.
Several research firms recently weighed in on CELG. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a report on Thursday, August 10th. Oppenheimer Holdings, Inc. set a $166.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Thursday. Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 27th. UBS AG lowered shares of Celgene Corporation from a “strong-buy” rating to a “market perform” rating and set a $160.00 target price on the stock. in a report on Thursday, October 26th. Finally, BMO Capital Markets reduced their target price on shares of Celgene Corporation from $163.00 to $148.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Celgene Corporation currently has a consensus rating of “Buy” and an average target price of $139.64.
COPYRIGHT VIOLATION WARNING: “Celgene Corporation (CELG) Shares Sold by Fiera Capital Corp” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/11/17/celgene-corporation-celg-shares-sold-by-fiera-capital-corp.html.
In other Celgene Corporation news, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now owns 85,551 shares in the company, valued at approximately $12,110,599.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,227 shares of company stock worth $2,843,956. Company insiders own 0.95% of the company’s stock.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.